MX338438B - Derivados de isoindolinona. - Google Patents

Derivados de isoindolinona.

Info

Publication number
MX338438B
MX338438B MX2013011732A MX2013011732A MX338438B MX 338438 B MX338438 B MX 338438B MX 2013011732 A MX2013011732 A MX 2013011732A MX 2013011732 A MX2013011732 A MX 2013011732A MX 338438 B MX338438 B MX 338438B
Authority
MX
Mexico
Prior art keywords
compounds
prophylaxis
disorders
treatment
diabetes mellitus
Prior art date
Application number
MX2013011732A
Other languages
English (en)
Other versions
MX2013011732A (es
Inventor
Steven Joseph Berthel
Robert Francis Kester
Lucja Orzechowski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013011732A publication Critical patent/MX2013011732A/es
Publication of MX338438B publication Critical patent/MX338438B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I), así como también sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas que contiene tales compuestos y métodos para usar tales compuestos en el tratamiento o profilaxis de enfermedades y trastornos. Los compuestos y compuestos descritos en la presente son activadores de glucosa-cinasa útiles para el tratamiento o profilaxis de enfermedades y trastornos metabólicos, por ejemplo diabetes mellitus, que incluye diabetes mellitus tipo II.
MX2013011732A 2011-05-03 2012-04-30 Derivados de isoindolinona. MX338438B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481789P 2011-05-03 2011-05-03
PCT/EP2012/057876 WO2012150202A1 (en) 2011-05-03 2012-04-30 Isoindolinone derivatives

Publications (2)

Publication Number Publication Date
MX2013011732A MX2013011732A (es) 2013-11-01
MX338438B true MX338438B (es) 2016-04-18

Family

ID=46022259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011732A MX338438B (es) 2011-05-03 2012-04-30 Derivados de isoindolinona.

Country Status (11)

Country Link
US (2) US8470866B2 (es)
EP (1) EP2705033A1 (es)
JP (1) JP6023176B2 (es)
KR (1) KR20140047046A (es)
CN (1) CN103502242B (es)
BR (1) BR112013027982A2 (es)
CA (1) CA2832390A1 (es)
HK (1) HK1191331A1 (es)
MX (1) MX338438B (es)
RU (1) RU2013152140A (es)
WO (1) WO2012150202A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
EP2318370A1 (en) * 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls

Also Published As

Publication number Publication date
CN103502242B (zh) 2016-01-20
CA2832390A1 (en) 2012-11-08
CN103502242A (zh) 2014-01-08
HK1191331A1 (zh) 2014-07-25
RU2013152140A (ru) 2015-06-10
BR112013027982A2 (pt) 2017-01-17
WO2012150202A1 (en) 2012-11-08
MX2013011732A (es) 2013-11-01
KR20140047046A (ko) 2014-04-21
EP2705033A1 (en) 2014-03-12
JP6023176B2 (ja) 2016-11-09
JP2014513108A (ja) 2014-05-29
US8470866B2 (en) 2013-06-25
US8697705B2 (en) 2014-04-15
US20130296339A1 (en) 2013-11-07
US20120283271A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
TN2013000309A1 (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201390381A1 (ru) Триазиноксадиазолы
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
MX343706B (es) Derivados heterocíclicos novedosos.
MX2010009922A (es) Activadores de piridazinona glucocinasa.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
IN2014CN04530A (es)
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
MX2013013950A (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2012006287A (es) Activadores de azaindol glucocinasa.
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.

Legal Events

Date Code Title Description
FG Grant or registration